Introduction: Unfortunately the restless leg syndrome (RLS) is a neglected issue among
hemodialysis (HD) centers.
Objectives: The aim of our study was to find the efficacy of gabapentin at a low dose of 100 mg
three times a week among HD patients with RLS.
Patients and Methods: Around 21 patients with fulfilled the criteria of RLS were randomized
to receive either gabapentin (100 mg) or placebo after HD session for 4 weeks. After 2 weeks
of washout period, the patients were switched from gabapentin to placebo or placebo to
gabapentin for another 4 weeks. Severity of RLS symptoms before and after management with
medication or placebo was evaluated with standardized questionnaire.
Results: Twenty-one patients (10 females and 11 males with mean age of 58 years) were enrolled
to the study. Before the study, all patients had questionnaire scores of 16 or greater and the
mean score was 24.19± 7.96. After gabapentin administration (before or after crossover),
the mean score significantly decreased from 24.19± 7.96 to 19.24± 9.87 (P=0.04). The mean
score before and after placebo administration (before or after crossover) were 24.19± 7.96 and
18.89± 11.15 with no significant difference (P=0.09).
Conclusion: According to the results of the study gabapentin at a dose of 100 mg at the end of
HD is a safe effective therapy for RLS. It can significantly reduce the intensity of RLS among